Cargando…
Aerosol Release by Healthy People during Speaking: Possible Contribution to the Transmission of SARS-CoV-2
Our research aimed to review the potential risk of infection by SARS-CoV-2. We used an excerpt of a data set generated in May 2020 for reviewing the SARS-CoV-2 prevention concept of orchestras, singers and actors. People were sampled for droplet release for one-hour activities using a Grimm spectrom...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730990/ https://www.ncbi.nlm.nih.gov/pubmed/33291404 http://dx.doi.org/10.3390/ijerph17239088 |
Sumario: | Our research aimed to review the potential risk of infection by SARS-CoV-2. We used an excerpt of a data set generated in May 2020 for reviewing the SARS-CoV-2 prevention concept of orchestras, singers and actors. People were sampled for droplet release for one-hour activities using a Grimm spectrometer covering a spectrum of 1 to 32 µm diameter. We estimated the number of “quanta” in the exhaled liquid from viral concentrations of 10(6) to 10(11)/mL, based on the Human Infective Dose 50 of 218 viral particles. We employed the Wells–Riley equation to estimate the risk of infection in typical meeting rooms for a one-hour meeting of 2, 4 and 6 people observing a 2 m distance. The four participating adults released a mean of 1.28 nLm(3) while breathing, 1.68 nL/m(3) while speaking normally, and two adults released a mean of 4.44 nL/m(3) while talking with a raised voice. The combination of 50% breathing, 45% talking normally and 5% speaking with a raised voice increased the risk of infection above 5% for a one-hour meeting of two people. The result is based on 6 quanta released, corresponding to an initial virus concentration of 1000/nL (10(9)/mL) in the fluid of the upper respiratory tract. Our data confirm the importance of using facemasks in combination with other measures to prevent transmission of SARS-CoV-2 at the workplace. |
---|